GRI Bio, Inc. Cash Flow Statement
GRI|1 years of annual SEC 10-K data (FY2021-FY2021)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid. All figures from audited SEC 10-K filings.
GRI Bio, Inc. used $4M in operating cash flow and negative free cash flow of $4M in FY2021.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 |
|---|---|
| Net Income | -$4.8M |
| Operating Cash Flow | -$3.7M |
| Capital Expenditures | $2.0K |
| Free Cash Flow | -$3.7M |
| FCF Margin | -3708.0% |